Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Molecular responses to immune checkpoint blockade in glioblastoma

(2019) Hirotaka Ito et al.   NATURE MEDICINE

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

(2019) William Tomaszewski et al.   CLINICAL CANCER RESEARCH

Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma

(2018) John A. Barrett et al.   CANCER GENE THERAPY

T-cell Dysfunction in Glioblastoma: Applying a New Framework

(2018) Karolina I. Woroniecka et al.   CLINICAL CANCER RESEARCH

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

(2018) Frederick F. Lang et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes after second surgery for recurrent glioblastoma: a retrospective case–control study

(2018) Alysson Wann et al.   JOURNAL OF NEURO-ONCOLOGY

Recurrent Glioblastoma Treated with Recombinant Poliovirus

(2018) Annick Desjardins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

(2018) Franz L. Ricklefs et al.   Science Advances

Abstract 2256: Efficient large-scale cell classification and analysis for MultiOmyxTMassays: A deep learning approach

(2018) Mate L. Nagy et al.   CANCER RESEARCH

Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier

(2018) Martina Da Ros et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

(2018) E Antonio Chiocca et al.   NEURO-ONCOLOGY

Pseudoprogression after glioma therapy: an update

(2017) Norbert Galldiks et al.   Expert Review of Neurotherapeutics

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

(2017) Benjamin M. Ellingson et al.   JOURNAL OF NEURO-ONCOLOGY

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer

(2017) Amanda Rosewell Shaw et al.   MOLECULAR THERAPY

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pseudoprogression after glioma therapy: an update

(2017) Norbert Galldiks et al.   Expert Review of Neurotherapeutics

Re: Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma

(2016) T.C. Booth et al.   CLINICAL RADIOLOGY

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma

(2016) Alba A. Brandes et al.   NEURO-ONCOLOGY

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

(2016) Alba A. Brandes et al.   NEURO-ONCOLOGY

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial

(2016) Bogdana Suchorska et al.   NEURO-ONCOLOGY

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

(2016) Lee A. Wheeler et al.   NEURO-ONCOLOGY

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

(2016) Timothy F. Cloughesy et al.   Science Translational Medicine

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

(2015) L. Zhang et al.   CLINICAL CANCER RESEARCH

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

(2015) Hideho Okada et al.   LANCET ONCOLOGY

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

(2015) Kathryn M. Field et al.   NEURO-ONCOLOGY

Immunosuppressive mechanisms in glioblastoma: Fig. 1.

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity

(2015) Mona Meyer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Evidence of Glioblastoma Heterogeneity

(2015) Akio Soeda et al.   Scientific Reports

Interleukin 12: still a promising candidate for tumor immunotherapy?

(2014) Witold Lasek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Microenvironmental Clues for Glioma Immunotherapy

(2014) Michael Platten et al.   Current Neurology and Neuroscience Reports

Critical constraint on inflationary magnetogenesis

(2014) Tomohiro Fujita et al.   JOURNAL OF COSMOLOGY AND ASTROPARTICLE PHYSICS

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

(2014) A. P. Patel et al.   SCIENCE

The Controversial Role of Microglia in Malignant Gliomas

(2013) Jun Wei et al.   Clinical & Developmental Immunology

Glioblastoma and Other Malignant Gliomas

(2013) Antonio Omuro   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection

(2013) Johannes vom Berg et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level

(2013) Justyna Kmiecik et al.   JOURNAL OF NEUROIMMUNOLOGY

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

(2013) A. Sottoriva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue

(2013) M. J. Gerdes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

(2013) David A. Nathanson et al.   SCIENCE

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

(2012) Roger Stupp et al.   EUROPEAN JOURNAL OF CANCER

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity

(2009) H Komita et al.   CANCER GENE THERAPY

Pseudoprogression and pseudoresponse in the treatment of gliomas

(2009) Dieta Brandsma et al.   CURRENT OPINION IN NEUROLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage therapy with single agent bevacizumab for recurrent glioblastoma

(2009) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma

(2008) E Antonio Chiocca et al.   MOLECULAR THERAPY